Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Acute Lymphoblastic Leukaemia in the Youngest: Haematopoietic Stem Cell Transplantation and Beyond

Research output: Contribution to journalReviewpeer-review

DOI

  1. Cerebral oximetry in preterm infants – to use or not to use, that is the question

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Cerebral Oximetry in Preterm Infants-To Use or Not to Use, That Is the Question

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Clinical outcome and gut development after insulin-like growth factor-1 supplementation to preterm pigs

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Male gonadal function after pediatric hematopoietic stem cell transplantation: a systematic review

    Research output: Contribution to journalReviewpeer-review

  2. Hematopoietic stem cell transplantation for Wiskott-Aldrich syndrome: an EBMT Inborn Errors Working Party analysis

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Anti-CD19 CAR T cells administration was feasible in a child with primary hepatitis B infection

    Research output: Contribution to journalLetterpeer-review

  • Adriana Balduzzi
  • Jochen Buechner
  • Marianne Ifversen
  • Jean-Hugues Dalle
  • Anca M Colita
  • Marc Bierings
View graph of relations

The ALL SCTped 2012 FORUM (For Omitting Radiation Under Majority age) trial compared outcomes for children ≥4 years of age transplanted for acute lymphoblastic leukaemia (ALL) who were randomised to myeloablation with a total body irradiation (TBI)-based or chemotherapy-based conditioning regimen. The TBI-based preparation was associated with a lower rate of relapse compared with chemoconditioning. Nevertheless, the age considered suitable for TBI was progressively raised over time to spare the most fragile youngest patients from irradiation-related complications. The best approach to use for children <4 years of age remains unclear. Children diagnosed with ALL in their first year of life, defined as infants, have a remarkably poorer prognosis compared with older children. This is largely explained by the biology of their ALL, with infants often carrying a KMT2A gene rearrangement, as well as by their fragility. In contrast, the clinical presentations and biological features of ALL in children >1 year but <4 years often resemble those presented by older children. In this review, we explore the state of the art regarding haematopoietic stem cell transplantation (HSCT) in children <4 years, the preparative regimens available, and new developments in the field that may influence treatment decisions.

Original languageEnglish
Article number807992
JournalFrontiers in Pediatrics
Volume10
Pages (from-to)807992
ISSN2296-2360
DOIs
Publication statusPublished - 2022

Bibliographical note

Copyright © 2022 Balduzzi, Buechner, Ifversen, Dalle, Colita and Bierings.

ID: 79733819